Multiple Sclerosis Patents (Class 514/903)
-
Patent number: 5506224Abstract: N-acyl-derivatives of hydroxyamines suitable for the therapeutic treatment of pathologies characterized by degranulation of mast cells caused by a neurogenic and/or immunogenic hyperstimulation.Type: GrantFiled: November 8, 1993Date of Patent: April 9, 1996Assignee: Lifegroup S.P.A.Inventors: Francesco della Valle, Silvana Lorenzi, Jacobus C. J. J. Samson, Federica della Valle
-
Patent number: 5472947Abstract: A composition for the treatment or prevention of multiple sclerosis is disclosed. It comprises mizoribine (4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate) as the effective component. It is a safe drug, exhibiting a minimal degree of side-effects, and thus can be administered over a long period of time. Administration of the drug, usually 1-20 mg/kg (body weight) per day for adults, improves the functional disturbances of multiple sclerosis.Type: GrantFiled: July 28, 1994Date of Patent: December 5, 1995Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Takahiko Saida, Kyoko Saida
-
Patent number: 5466675Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;are provided.Type: GrantFiled: July 20, 1994Date of Patent: November 14, 1995Inventors: Goran Piljac, Visnja Piljac
-
Patent number: 5464816Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.Type: GrantFiled: March 26, 1990Date of Patent: November 7, 1995Assignee: Mitsui Pharmaceuticals Inc.Inventors: Yoshitaka Nagai, Hayao Abe, Masanobu Arita
-
Patent number: 5457129Abstract: A novel method of inhibiting production of two important mediators of cellular function, tumor necrosis factor and nitric oxide, and treating a pathophysiological state characterized by an undesirable production or level of tumor necrosis factor or nitric acid. The methods of the present invention employ retinoic acid compounds. The most preferred retinoic acid is all-trans-retinoic acid.Type: GrantFiled: May 17, 1993Date of Patent: October 10, 1995Assignee: Research Development FoundationInventors: Bharat B. Aggarwal, Kapil Mehta
-
Patent number: 5434166Abstract: A method of inhibiting demyelinating or dysmyelinating diseases or their symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 22, 1994Date of Patent: July 18, 1995Assignee: Eli Lilly and CompanyInventor: Andrew L. Glasebrook
-
Patent number: 5344844Abstract: A salt-excretion promoting composition, characterized by containing (i) 10 parts by weight of agar and (ii) 1 to 15 parts by weight of at least one polysaccharide selected from the group consisting of sodium alginate, .lambda.- and .kappa.-carrageenan and xanthane gum.Type: GrantFiled: December 30, 1992Date of Patent: September 6, 1994Assignee: Kabushiki Kaisya AdvanceInventor: Kazuoki Ishihara
-
Patent number: 5338730Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.Type: GrantFiled: June 4, 1993Date of Patent: August 16, 1994Assignee: Sandoz Ltd.Inventors: Heinrich Estermann, Prasad K. Kapa, Russell L. Underwood, William J. Houlihan
-
Patent number: 5322838Abstract: The present invention relates to the use of INHIB in the detection and inhibition of inflammation. INHIB is structurally identical to the C3 .beta.-chain.Type: GrantFiled: October 16, 1991Date of Patent: June 21, 1994Assignee: Brigham & Women's HospitalInventors: David S. Silberstein, Marjorie Minkoff
-
Patent number: 5308837Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.Type: GrantFiled: November 12, 1992Date of Patent: May 3, 1994Assignee: Merrell Dow Pharmaceuticals Inc.Inventor: Terry L. Bowlin
-
Patent number: 5284836Abstract: The invention discloses certain heterocyclic, thioether, keto-ester and alkyl phospholipids, e.g., heterocyclic phospholipids having the formula ##STR1## where R is n-C.sub.14 -C.sub.20 alkyl or O-n-C.sub.14 -C.sub.20 alkyl; each R.sub.1 is methyl or ethyl; n is 2-6; and X is --CH.sub.2 --m, where m is 2-4, CH.sub.2 CH.sub.2 O or CH.sub.2 CH.sub.2 S, or a corresponding hydrate thereof, which compounds are useful in treating multiple sclerosis.Type: GrantFiled: December 4, 1992Date of Patent: February 8, 1994Assignee: Sandoz Ltd.Inventor: William J. Houlihan
-
Patent number: 5246970Abstract: A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.Type: GrantFiled: June 30, 1992Date of Patent: September 21, 1993Assignee: Washington UniversityInventors: Joseph R. Williamson, John A. Corbett, Michael L. McDaniel, Ronald G. Tilton
-
Patent number: 5229377Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.Type: GrantFiled: April 26, 1991Date of Patent: July 20, 1993Assignee: Sandoz Ltd.Inventors: Heinrich Estermann, Prasad K. Kapa, Russell L. Underwood, William J. Houlihan
-
Patent number: 5227369Abstract: The present invention provides pharmaceutical compositions and methods for treating demyelinating diseases. The compositions comprise a blocking agent which inhibits LHR-mediated binding of leukocytes to myelin.Type: GrantFiled: July 11, 1991Date of Patent: July 13, 1993Assignee: The Regents of the University of CaliforniaInventors: Steven Rosen, Kun Huang, Mark Singer, Joyce Geoffroy
-
Patent number: 5196430Abstract: A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.Type: GrantFiled: September 18, 1991Date of Patent: March 23, 1993Assignees: Hoechst-Roussel Pharmaceuticals Inc., University of Virginia Alumni Patents FoundationInventors: Gerald L. Mandell, Gail W. Sullivan, William J. Novick
-
Patent number: 5194425Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X.sup.1 MHC.sup.2 peptide or MHC.sup.2 peptide.sup.1 X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; .sup.1 represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and .sup.2 represents a covalent bond, a noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.Type: GrantFiled: June 21, 1989Date of Patent: March 16, 1993Assignee: Anergen, Inc.Inventors: Somesh D. Sharma, L. Bernard Lerch, Brian R. Clark
-
Patent number: 5189026Abstract: A method of preventing, treating and/or controlling diseases caused by dysregulation and/or dysfunction of various portions of the nervous system which comprises administering to a patient, an effective amount of a compound of the avermectin family, e.g. ivermectin, in single or multiple doses of up to 1.6 mg/kg at intervals of from 3 days to 4 months.Type: GrantFiled: June 7, 1991Date of Patent: February 23, 1993Assignee: Fractal Laboratories, Inc.Inventors: Jonathan L. Costa, Jesus A. Diazgranados
-
Patent number: 5182271Abstract: The invention discloses certain thioether, keto-ester and alkyl phospholipids which are useful in treating multiple sclerosis.Type: GrantFiled: August 30, 1991Date of Patent: January 26, 1993Assignee: Sandoz Ltd.Inventor: William J. Houlihan
-
Patent number: 5130297Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X--MHC--peptide or MHC--peptide--X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; -- represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and -- represents a covalent bond, to noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.Type: GrantFiled: August 30, 1990Date of Patent: July 14, 1992Assignee: Anergen, Inc.Inventors: Somesh D. Sharma, L. Bernard Lerch, Brian R Clark
-
Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases
Patent number: 5114721Abstract: Pharmaceutical preparations are provided for preventing or treating autoimmune diseases in which the active principle is activated T-lymphocyte cells, specific for the autoimmune disease to be treated, which cells have been treated by incubation with a photoactivatable psoralen cross-linking agent, such as 8-methoxypsoralen, and then photoactivated. The active principle may also be the membrane fraction of such cells. Such preparations may be formulated into pharmaceutical compositions and administered to prevent or treat autoimmune disesases.Type: GrantFiled: March 15, 1989Date of Patent: May 19, 1992Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Meir Shinitzky, Richard L. Edelson -
Patent number: 5112810Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.Type: GrantFiled: May 15, 1985Date of Patent: May 12, 1992Assignee: Mitsui Pharmaceuticals, Inc.Inventors: Yoshitaka Nagai, Hayao Abe, Masanobu Arita
-
Patent number: 5102883Abstract: The pyrimidine biosynthesis inhibitors dichloroallyl lawsone, N-(phosphonoacetyl)-L-aspartic acid (PALA), pyrazofurin, and derivatives thereof, are useful as immunomodulatory and anti-inflammatory agents. Pharmaceutical formulations containing these compounds are useful for the treatment of autoimmune diseases, chronic inflammatory diseases, and of organ transplantation rejections.Type: GrantFiled: October 31, 1989Date of Patent: April 7, 1992Assignee: Du Pont Merck Pharmaceutical CompanyInventors: Neil R. Ackerman, Bruce D. Jaffee
-
Patent number: 5093317Abstract: Method of enhancing the survival of neuronal cells, more preferably non-mitotic neuronal cells and/or cholinergic cells in a mammal, which cells are at risk of dying, which method includes administering to the mammal an effective amount of a functional derivative of Insulin-like Growth Factor I or Insulin-like Growth Factor II.Type: GrantFiled: June 5, 1989Date of Patent: March 3, 1992Assignee: Cephalon, Inc.Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Jr.
-
Patent number: 5064816Abstract: invention relates to heterocyclic phospholipids of formula III which are useful in treating multiple sclerosis:where R .sub.2 is n-C.sub.14 -C.sub.20 alkyl;each R.sub.1, independently, is methyl or ethyl; Y is --O-- or --S--;n is an integer 2 to 6.Type: GrantFiled: June 5, 1990Date of Patent: November 12, 1991Assignee: Sandoz Ltd.Inventor: William J. Houlihan
-
Patent number: 5055290Abstract: A method of selectively suppressing the excess immune reaction produced iatrogenically or autochthonously by administering 0.1 to 100 mg of ciamexone per kg of body weight.Type: GrantFiled: May 25, 1988Date of Patent: October 8, 1991Assignee: Boehringer Mannehim GmbHInventors: Uwe Bicker, Wulf Pahlke
-
Patent number: 5051438Abstract: This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof ##STR1## wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl and m is 1 or 2;R.sup.1 is alkyl of 1 to 4 carbon atoms;R.sup.2 is hydrogen or alkyl of 1 to 5 carbon atoms;R.sup.4 is alkyl of 1 to 6 carbon atoms;n is an integer from 1 to 5; andY is NH or oxygen.The compounds of Formula I are leukotriene B.sub.4 antagonists and are useful as anti-inflammatory agents and in the treatment of LTB.sub.4 mediated diseases.Type: GrantFiled: May 16, 1990Date of Patent: September 24, 1991Assignee: G. D. Searle & Co.Inventors: Stevan W. Djuric, Thomas D. Penning
-
Patent number: 5043355Abstract: The use is disclosed of compounds of general formula ##STR1## wherein: Y is methyl, andR is an unsubstituted or substituted alkyl group selected from methyl, or ethyl,and the pharmacologically acceptable salts thereof, for treating peripheral neuropathies.The compounds can be administered orally or parenterally.Type: GrantFiled: December 15, 1989Date of Patent: August 27, 1991Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Patent number: 5036102Abstract: A method of treating leukocyte mediated autoimmune and skin diseases using psoralen reagent composition comprising sterile aqueous solutions suitable for extracorporeal administration to blood from a subject being treated by ultraviolet-A photophoresis.Type: GrantFiled: September 14, 1990Date of Patent: July 30, 1991Assignee: Hoffmann-La Roche Inc.Inventors: Maria O. Bachynsky, Martin H. Infeld, Richard J. Margolis, Dennis A. Perla
-
Patent number: 5001119Abstract: Compounds of the formula: ##STR1## are useful as anti-cancer, anti-obesity, anti-diabetic, anti-coronary agents, anti-aging agents, anti-hypolipidemic agents and anti-autoimmune agents.Type: GrantFiled: November 25, 1987Date of Patent: March 19, 1991Inventors: Arthur G. Schwartz, Marvin L. Lewbart
-
Patent number: 4994466Abstract: A method of treating a patient suffering from multiple sclerosis comprising daily administration to such patient of from about 1 to about 100 mg of a pure narcotic antagonist, e.g., nalmefene or naltrexone. The antagonist may be administered in divided doses from one to four times daily, preferably by the oral route. Parenteral, transmucosal and transdermal administration may be utilized where suitable.Type: GrantFiled: June 14, 1990Date of Patent: February 19, 1991Assignee: Baker Cummins Pharmaceuticals, Inc.Inventors: Fred P. Sherman, Elliot Hahn
-
Patent number: 4950687Abstract: A therapeutic treatment for the athrosis diseases comprising administering by intraarticular route from 1 to 5 ml of an aqueous solution containing from 10 to 50 mg of a diacetyl rhein salt having formula (I): ##STR1## wherein M represents an alkali or an earth alkali metal or the residue of an organic base.The diacetyl rhein salts administered by intraarticular route exhibit higher pharmacological activity than the corresponding diacetylrhein administered orally.Type: GrantFiled: July 17, 1989Date of Patent: August 21, 1990Assignee: Proter S.p.A.Inventors: Leone Dall'Asta, Germano Coppi, Mario Ercole Scevola
-
Patent number: 4898856Abstract: A method of treating humans suffering from central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, senile dimentia. The treatment consists of inducing into the patient's blood stream at least one from the group consisting of: sex hormones and anabolic hormones. Growth hormone is also be used in those patients in advanced stages of the disease, or in those patients where it has been determined that a low level of growth hormone is present. A method of diagnosing Alzheimer's disease, senile dementia, by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the Aroonsakyl-Allen provocative test is also disclosed. Blood-sera samples are taken at certain time periods after the administration of L-Dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects.Type: GrantFiled: February 16, 1988Date of Patent: February 6, 1990Inventor: Chaovanee Aroonsakul
-
Patent number: 4741902Abstract: The invention provides compositions of matter having pharmacological activity and which are useful in the treatment of the symptoms of neurological and other disorders, particularly those disorders which are caused by malfunction of the immune mechanism. The present compositions include venoms and/or venom fractions extracted from various elapid and viperid snakes and generally include a postsynaptic component capable of binding to nicotinic acetylcholine receptors of cells, a presynaptic component capable of inhibition of acetylcholine release, and a viperid component stimulative of the immune system. According to the present invention, the viperid component of the present compositions of matter preferably constitutes a venom fraction which is absent certain enzymes such as L-amino acid oxidase and phosphodiesterase, these compositions being of particular utility due to the absence of a hemorrhagic effect when used in the treatment of mammals.Type: GrantFiled: July 14, 1986Date of Patent: May 3, 1988Inventor: William E. Haast
-
Patent number: 4657761Abstract: A non-specific therapeutic polyvalent vaccine for subcutaneous injection containing a minimum combination of a PPD (tuberculin vaccine), a rabies vaccine, and snake venom vaccine and preferably including at least a DTP vaccine in addition and optimally a mumps antigen vaccine and Dermatophytin vaccine in controlled levels, all such constituent vaccines being commercially available. The vaccine provides a broad-based stimulation or potentiation of the immuno-defense system of the patient and is useful for the symptomatic relief and/or mitigation of diseases of viral origin, such as Herpes Zoster, labialis and genitalis, various neuralgias, mumps, measles, viral hepatitis, psoriasis and severe acne, or of autoimmune origin, such as multiple sclerosis and arthritis.Type: GrantFiled: June 5, 1985Date of Patent: April 14, 1987Inventor: Cesar M. Pinto
-
Patent number: 4618601Abstract: This invention relates to the use of zinc gluconate for making a medicament administered by the oral route and containing from 50 to 150 mg of zinc gluconate, said medicament being used for the treatment of hyperprolactinaemias.Type: GrantFiled: December 3, 1985Date of Patent: October 21, 1986Assignee: 501 Societe Civile de Recherches et d'Etudes TheraputiquesInventors: Guy Chazot, Catherine Suck